Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2024-07-30 Legal Proceedings Report
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
불성실공시법인미지정 (지정유예)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory announcement from the KOSDAQ market regarding the status of a company (OliX) as a 'non-designated' entity for unfair disclosure practices. It details the regulatory decision, the grounds for the decision (deferral of designation), and references specific market disclosure regulations. Since this is a formal regulatory notice regarding compliance and disclosure status that does not fit into specific financial reporting or corporate action categories, it is classified as a Regulatory Filing (RNS).
2024-07-30 Korean
기타경영사항(자율공시) (전환우선주의 보통주 전환청구(제1회차, 제2회차))
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding the conversion of convertible preferred shares into common shares. This involves a change in the company's capital structure and the issuance of new common shares. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements regarding new share issues or capital changes resulting from conversions.
2024-07-22 Korean
불성실공시법인지정예고 (공시번복 2건)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange (KOSDAQ) regarding the 'pre-designation of an unfaithful disclosure corporation' (불성실공시법인지정예고). It details specific regulatory actions taken against the company 'OliX' due to disclosure violations (contract cancellations). This is a regulatory announcement regarding compliance and legal/regulatory status, which fits best under the 'Regulatory Filings' (RNS) category as it does not fall into specific financial reporting or corporate action categories like M&A or dividends.
2024-07-12 Korean
투자판단관련주요경영사항 (건성 및 습성 황반변성 치료제 OLX301A, 습성황반변성 및 망막하섬유화증 치료제 OLX301D 기술이전 계약해지 및 권리 반환)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a material management event ('투자판단 관련 주요경영사항'). It specifically announces the termination of a technology transfer agreement for drug candidates (OLX301A and OLX301D). Since this is a formal regulatory announcement of a material business event that does not fit into specific categories like M&A (which usually implies a corporate merger/acquisition) or financial reports, it is classified as a general regulatory filing (RNS).
2024-06-24 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (OLX75016비알코올성지방간염 치료제의 호주 제1상 임상시험 계획 변경승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (OliX) submitted to the KRX (Korea Exchange). It details a 'Major Management Matter' regarding the approval of a clinical trial plan amendment. This type of disclosure is a standard regulatory requirement for publicly traded companies to inform shareholders of material developments in their R&D pipeline. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-05-30 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (OLX75016(비알코올성지방간염 치료제)의 호주 제1상 임상시험 계획 변경승인 신청)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Olix) submitted to the KRX (Korea Exchange). It details a 'Major Management Matter' regarding an application for an amendment to a clinical trial plan (OLX75016). This type of disclosure is a standard regulatory announcement for material corporate events, specifically related to R&D and clinical trial progress. Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category.
2024-05-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.